45
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell‐free products and human pluripotent stem cell‐derived mesenchymal stem cells

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mesenchymal stem cell therapy (MSCT) for immune and inflammatory diseases continues to be popular based on progressive accumulation of preclinical mechanistic evidence. This has led to further expansion in clinical indications from graft rejection, autoimmune diseases, and osteoarthritis, to inflammatory liver and pulmonary diseases including COVID‐19. A clear trend is the shift from using autologous to allogeneic MSCs, which can be immediately available as off‐the‐shelf products. In addition, new products such as cell‐free exosomes and human pluripotent stem cell (hPSC)‐derived MSCs are exciting developments to further prevalent use. Increasing numbers of trials have now published results in which safety of MSCT has been largely demonstrated. While reports of therapeutic endpoints are still emerging, efficacy can be seen for specific indications—including graft‐vs‐host‐disease, strongly Th17‐mediated autoimmune diseases, and osteoarthritis—which are more robustly supported by mechanistic preclinical evidence. In this review, we update and discuss outcomes in current MSCT clinical trials for immune and inflammatory disease, as well as new innovation and emerging trends in the field.

          Abstract

          Broad immunomodulatory properties of human tissue and pluripotent stem cell‐derived mesenchymal stem cells (MSCs), as well as MSC‐derived products toward multiple types of immune cells allow for therapeutic use toward a spectrum of immune and inflammatory disorders.

          Related collections

          Most cited references188

          • Record: found
          • Abstract: found
          • Article: not found

          Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

          The considerable therapeutic potential of human multipotent mesenchymal stromal cells (MSC) has generated markedly increasing interest in a wide variety of biomedical disciplines. However, investigators report studies of MSC using different methods of isolation and expansion, and different approaches to characterizing the cells. Thus it is increasingly difficult to compare and contrast study outcomes, which hinders progress in the field. To begin to address this issue, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC. First, MSC must be plastic-adherent when maintained in standard culture conditions. Second, MSC must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules. Third, MSC must differentiate to osteoblasts, adipocytes and chondroblasts in vitro. While these criteria will probably require modification as new knowledge unfolds, we believe this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

            Adult bone-marrow-derived mesenchymal stem cells are immunosuppressive and prolong the rejection of mismatched skin grafts in animals. We transplanted haploidentical mesenchymal stem cells in a patient with severe treatment-resistant grade IV acute graft-versus-host disease of the gut and liver. Clinical response was striking. The patient is now well after 1 year. We postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment.

              The identity of cells that establish the hematopoietic microenvironment (HME) in human bone marrow (BM), and of clonogenic skeletal progenitors found in BM stroma, has long remained elusive. We show that MCAM/CD146-expressing, subendothelial cells in human BM stroma are capable of transferring, upon transplantation, the HME to heterotopic sites, coincident with the establishment of identical subendothelial cells within a miniature bone organ. Establishment of subendothelial stromal cells in developing heterotopic BM in vivo occurs via specific, dynamic interactions with developing sinusoids. Subendothelial stromal cells residing on the sinusoidal wall are major producers of Angiopoietin-1 (a pivotal molecule of the HSC "niche" involved in vascular remodeling). Our data reveal the functional relationships between establishment of the HME in vivo, establishment of skeletal progenitors in BM sinusoids, and angiogenesis.
                Bookmark

                Author and article information

                Contributors
                mlyen@ntu.edu.tw
                blyen@nhri.edu.tw
                Journal
                Stem Cells Transl Med
                Stem Cells Transl Med
                10.1002/(ISSN)2157-6580
                SCT3
                Stem Cells Translational Medicine
                John Wiley & Sons, Inc. (Hoboken, USA )
                2157-6564
                2157-6580
                19 May 2021
                September 2021
                : 10
                : 9 ( doiID: 10.1002/sct3.v10.9 )
                : 1288-1303
                Affiliations
                [ 1 ] Department of Obstetrics & Gynecology National Taiwan University (NTU) Hospital & College of Medicine, NTU Taipei Taiwan Republic of China
                [ 2 ] National Institute of Cancer Research National Health Research Institutes (NHRI) Tainan Taiwan Republic of China
                [ 3 ] National Institute of Infectious Diseases & Vaccinology, NHRI Zhunan Taiwan Republic of China
                [ 4 ] Department & Graduate Institute of Microbiology & Immunology National Defense Medical Center Taipei Taiwan Republic of China
                [ 5 ] Regenerative Medicine Research Group Institute of Cellular & System Medicine, NHRI Zhunan Taiwan Republic of China
                Author notes
                [*] [* ] Correspondence

                Men‐Luh Yen, MD, PhD, Department of Obstetrics/Gynecology, NTUH & College of Medicine, NTU, No. 1, Section 1, Jen‐Ai Road, Taipei 10051, Taiwan, Republic of China.

                Email: mlyen@ 123456ntu.edu.tw

                B. Linju Yen, MD, 35 Keyan Road, Zhunan 35053, Taiwan, Republic of China.

                Email: blyen@ 123456nhri.edu.tw

                Author information
                https://orcid.org/0000-0002-6905-3018
                Article
                SCT312970
                10.1002/sctm.21-0021
                8380447
                34008922
                839c1c6a-8cdd-4876-9928-eb23ba29fb07
                © 2021 The Authors. stem cells translational medicine published by Wiley Periodicals LLC on behalf of AlphaMed Press.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 31 March 2021
                : 15 January 2021
                : 20 April 2021
                Page count
                Figures: 5, Tables: 2, Pages: 16, Words: 14143
                Categories
                Mesenchymal Stem Cells 
                Concise Review
                Concise Review
                Custom metadata
                2.0
                September 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.5 mode:remove_FC converted:22.08.2021

                autoimmune diseases,clinical trials,exosomes,extracellular vesicles,graft rejection,human,human pluripotent stem cells,liver cirrhosis,mesenchymal stem/stromal cell therapy,organ transplantation,pulmonary inflammation

                Comments

                Comment on this article

                scite_
                84
                0
                74
                0
                Smart Citations
                84
                0
                74
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content334

                Cited by49

                Most referenced authors4,641